Full Text
HTA308 Market Access for Anti-Cancer Drugs: Is the Demonstration of a Clinical Benefit on Survival Correlated With Price Level?

Abstract

Authors

L. Grangé I. Borget E. Duteil

Back to Volume 26, Supplemental Issue 12S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×